FDA's Buehler To Join Teva
This article was originally published in The Pink Sheet Daily
Executive Summary
The former head of the Office of Generic Drugs will become Teva's VP of regulatory strategic operations.
You may also be interested in...
Jenkins' Retirement From US FDA Was Several Years In The Making
Outgoing Office of New Drugs director dismisses speculation that his decision to leave the agency was related to events surrounding Sarepta's controversial Exondys 51 approval.
FDA Generic Office Director Uhl Returns From Medical Leave
Kathleen Uhl's five-month leave for cancer treatment ends as user fee negotiations move towards formal start.
FDA Generics Office To Be Managed By Relative Unknown
Director Uhl’s medical leave puts bioequivalence office head John Peters in the limelight.